Oxytocin in the Treatment of Psychiatric Disorders

被引:4
|
作者
Kagizman, Salim Cagatay [1 ]
Hocaoglu, Cicek [2 ]
机构
[1] Hitit Univ, Erol Olcok Training & Res Hosp, Dept Psychiat, Corum, Turkiye
[2] Recep Tayyip Erdogan Univ, Fac Med, Dept Psychiat, Rize, Turkiye
来源
MEDENIYET MEDICAL JOURNAL | 2023年 / 38卷 / 03期
关键词
Psychiatric disorders; oxytocin; schizophrenia; resistance to treatment; autism; ADJUNCTIVE INTRANASAL OXYTOCIN; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; SCHIZOPHRENIA; METAANALYSIS; REACTIVITY; WITHDRAWAL; WOMEN;
D O I
10.4274/MMJ.galenos.2023.13707
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Oxytocin is a peptide hormone that is most known for its role in reproduction. However, many effects other than reproduction have been defined. The lifetime prevalence of mental disorders is approximately 20%, and they have a significant ratio among the diseases that lead to disability. Treatment resistance may cause the mental disorder to become chronic and increase disability. With the examination of the oxytocinergic system, both the elucidation of the etiology of the diseases and their evaluation as a new treatment option have come to the fore. In various studies, it has been desired to create a more effective treatment model by measuring the level of oxytocin in psychiatric disorders, examining its receptor, and applying exogenous oxytocin in the treatment. In this review, an overview of oxytocin's efficacy in treatment is presented by considering the relationship between psychiatric disorders and the oxytocinergic system.
引用
收藏
页码:218 / 231
页数:14
相关论文
共 50 条
  • [1] The role of oxytocin and vasopressin dysfunction in cognitive impairment and mental disorders
    Abramova, Olga
    Zorkina, Yana
    Ushakova, Valeria
    Zubkov, Eugene
    Morozova, Anna
    Chekhonin, Vladimir
    NEUROPEPTIDES, 2020, 83
  • [2] Could intranasal oxytocin enhance the effects of psychotherapy in individuals with mental disorders? A systematic review and meta-analysis
    Perez-Arqueros, Valeska
    Soler, Joaquim
    Schmidt, Carlos
    Vega, Daniel
    Pascual, Juan C.
    PSYCHONEUROENDOCRINOLOGY, 2025, 171
  • [3] Involvement of oxytocin receptor deficiency in psychiatric disorders and behavioral abnormalities
    Wei, Jinbao
    Zheng, Huanrui
    Li, Guokai
    Chen, Zichun
    Fang, Gengjing
    Yan, Jianying
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2023, 17
  • [4] The Role of Oxytocin in Psychiatric Disorders: A Review of Biological and Therapeutic Research Findings
    Cochran, David M.
    Fallon, Daniel
    Hill, Michael
    Frazier, Jean A.
    HARVARD REVIEW OF PSYCHIATRY, 2013, 21 (05) : 219 - 247
  • [5] IS TREATMENT-RESISTANCE IN PSYCHIATRIC DISORDERS A TRAP FOR POLYPHARMACY?
    Jasovic-Gasic, Miroslava
    PSYCHIATRIA DANUBINA, 2015, 27 (03) : 308 - 313
  • [6] Exogenous effects of oxytocin in five psychiatric disorders: a systematic review, meta-analyses and a personalized approach through the lens of the social salience hypothesis
    Peled-Avron, Leehe
    Abu-Akel, Ahmad
    Shamay-Tsoory, Simone
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2020, 114 : 70 - 95
  • [7] Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis
    Keech, Britney
    Crowe, Simon
    Hocking, Darren R.
    PSYCHONEUROENDOCRINOLOGY, 2018, 87 : 9 - 19
  • [8] Oxytocin in the socioemotional brain: implications for psychiatric disorders
    Kirsch, Peter
    DIALOGUES IN CLINICAL NEUROSCIENCE, 2015, 17 (04) : 463 - 476
  • [9] Oxytocin system dysfunction as a common mechanism underlying metabolic syndrome and psychiatric symptoms in schizophrenia and bipolar disorders
    Quintana, Daniel S.
    Dieset, Ingrid
    Elvsashagen, Torbjorn
    Westlye, Lars T.
    Andreassen, Ole A.
    FRONTIERS IN NEUROENDOCRINOLOGY, 2017, 45 : 1 - 10
  • [10] The Role of Neurohypophyseal Hormones Vasopressin and Oxytocin in Neuropsychiatric Disorders
    Iovino, Michele
    Messana, Tullio
    De Pergola, Giovanni
    Iovino, Emanuela
    Dicuonzo, Franca
    Guastamacchia, Edoardo
    Giagulli, Vito Angelo
    Triggiani, Vincenzo
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2018, 18 (04) : 341 - 347